In:
Pathobiology, S. Karger AG, Vol. 89, No. 6 ( 2022), p. 393-406
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 The neurotrophic tropomyosin-related kinase ( 〈 i 〉 NTRK 〈 /i 〉 ) genes encode the tropomyosin receptor kinases (TRKs). Patients with solid tumors harboring an oncogenic 〈 i 〉 NTRK 〈 /i 〉 fusion are eligible for treatment with TRK inhibitors. 〈 i 〉 NTRK 〈 /i 〉 fusion is often associated with TRK overexpression. Pan-TRK immunohistochemistry (IHC) is used to screen for 〈 i 〉 NTRK 〈 /i 〉 fusions, but immunoreactivity patterns are poorly defined. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Data on pan-TRK immunoreactivity patterns in 2,669 solid tumors (comprising carcinomas, sarcomas, and melanocytic lesions) were retrospectively collected by nine laboratories and comprised tumor type, percentage of pan-TRK-positive tumor cells, staining intensity, cytoplasmic, membrane and/or nuclear staining pattern, and the presence or absence of 〈 i 〉 NTRK 〈 /i 〉 fusion. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Overall, 2,457 tumors (92%) were pan-TRK negative and 212 neoplasms (8%) were pan-TRK positive. Twenty-two pan-TRK-positive tumors (0.8%) harbored an 〈 i 〉 NTRK 〈 /i 〉 fusion, representing 10% of all pan-TRK-positive tumors. Cytoplasmic immunoreactivity was most often observed, followed by membrane immunoreactivity. Nuclear pan-TRK positivity was least frequent, but was most often (33%) associated with 〈 i 〉 NTRK 〈 /i 〉 fusion. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Pan-TRK IHC can be used to screen for 〈 i 〉 NTRK 〈 /i 〉 fusions, especially in commonly diagnosed solid tumors with low 〈 i 〉 NTRK 〈 /i 〉 fusion prevalence. In case of pan-TRK immunoreactivity, regardless of its intensity and tumor cell percentage, subsequent molecular tests should be performed to formally confirm the presence or absence of 〈 i 〉 NTRK 〈 /i 〉 fusions.
Type of Medium:
Online Resource
ISSN:
1015-2008
,
1423-0291
Language:
English
Publisher:
S. Karger AG
Publication Date:
2022
detail.hit.zdb_id:
1483541-1
SSG:
12
Bookmarklink